6-Hydroxy-DL-DOPA - CAS 21373-30-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
6-Hydroxy-DL-DOPA is an allosteric inhibitor of RAD52 that suppresses RAD52 binding to single strand DNA binding domains (IC50 = 1.1 μM). 6-Hydroxy-DL-DOPA inhibits proliferation of BRCA-deficient cancer cells in vitro.
Brife Description:
allosteric inhibitor of RAD52
2,5-Dihydroxy-DL-tyrosine; 6-Hydroxydopa; 6-Ohdopa; 2,5-Dihydroxytyrosine; 2,4,5-Trihydroxyphenylalanine
Canonical SMILES:
1.6-hydroxydopa during development of central adrenergic neurons produces different long-term changes in rat brain noradrenaline.
Zieher LM;Jaim-Etcheverry G Brain Res. 1975 Mar 21;86(2):271-81.
6-hydroxydopa (6-OH-DOPA) administered to rats during their early development produces long-term modifications in the content of brain noradrenaline (NA) which have regional differences. An increase in brain stem NA is observed when the rats are exposed to the drug between the day 14 of gestation and the 9th postnatal day. When 6-OH-DOPA is injected subcutaneously on the 13th postnatal day or later, there is a decrease in brain stem NA. On the other hand, the content of NA in the telediencephalon is depleted for the first time in rats exposed to the drug during the day 16 of gestation, the decrease is more evident when the injection is done on days 17 or 18 and the effect is also marked when the drug is administered in the period between the day of birth and the 20th day of age. These results indicate that 6-OH-DOPA exerts different effects during the process of development and that the increase in brain stem NA is not solely dependent on the depletion produced in the forebrain because both phenomena are temporally dissociated. The adrenergic neurons injured by the drug, most probably respond in such a way that leads to an increase in brain stem NA only during the period in which they are under the influence of the factors controlling their physiologic development.
2.The influence of central chemical sympathectomy and reserpine on peripheral effects of noradrenaline and cyclic AMP dibutyrate injected into the cerebral ventricles.
Brus R;Herman ZS;Dzikowski A;Zabawska J Arch Immunol Ther Exp (Warsz). 1976;24(4):537-42.
Chemical sympathectomy of the central nervous system by injection of 6-hydroxy-dopamine (2 X 250 mug) or 6-hydroxydopa (90 mug) intensified some of the peripheral effects of noradrenaline and cyclic AMP dibutyrate injected into the cerebral ventricles. Reserpine (5 mg/kg) injected intraperitoneally weakened the peripheral reactions to noradrenaline injected intraventricularly. The results of the experiments indicate that peripheral reactions to intraventricularly injected noradrenaline depend on changes in the content of endogenous narodrenaline in the brain and on the mechanisms leading to these changes.
3.Amygdalar noradrenergic and dopaminergic mechanisms in the regulation of hunger and thirst-motivated behavior.
Lénárd L;Hahn Z Brain Res. 1982 Feb 4;233(1):115-32.
The feeding behavior of rats was studied after neurochemical damage of the amygdalar terminal fields of mesolimbic dopaminergic (DA) and coerular noradrenergic (NA) pathways. 6-Hydroxydopamine (6-OHDA) or 6-hydroxydopa (6-OHDOPA) were injected bilaterally into the central part of amygdala. 6-OHDA was also injected after desmethylimipramine (DMI) pretreatment in order to study the selective destruction of DA terminals. The body weight increased after 6-OHDA injection and a mild hyperphagia and hyperdipsia developed. The 6-OHDA plus DMI treatment resulted in body weight decrease, hypophagia and hypodipsia. These effects were dose-dependent. While a high dose of 6-OHDOPA (15 mug/mul) decreased the body weight, an increase of weight was observed after a low dose (4 mug/0.5 mul). After 6-OHDA, 6-OHDA plus DMI or the high dose of 6-OHDOPA the DA concentration dropped significantly in the amygdala while low-dose 6-OHDOPA resulted in DA increase. In every case there was a parallel change in striatal DA content. The amygdalar NA concentration decreased after both 6-OHDA and the high dose of 6-OHDOPA. There was no change in NA levels after 6-OHDA plus DMI treatment and the NA concentration increased after the injection of a low dose of 6-OHDOPA.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 1365986-44-2 Protein Kinase Inhibitors 1

Protein Kinase Inhibitors 1
(CAS: 1365986-44-2)

Protein Kinase Inhibitors 1 is a HIPK2 inhibitor with IC50 of 74 nM and Kd of 9.5 nM.

CAS 388592-44-7 CK 869

CK 869
(CAS: 388592-44-7)

CK 869 has been found to inhibit actin polymerization as well as human and bovine actin-related protein 2/3 (Arp2/3) complex.

CAS 308242-62-8 Remimazolam

(CAS: 308242-62-8)

Remimazolam, a benzodiazepine derivative, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, currently in Phase III clinical development for ...

CAS 98849-88-8 FLAG peptide

FLAG peptide
(CAS: 98849-88-8)

FLAG peptide, an eight amino acids peptide with an enterokinase-cleavage site, is a frequently applied hydrophilic and immunogenic fusion tag which was specific...

CAS 145854-59-7 Mas7

(CAS: 145854-59-7)

Mas7, a structural analogue of mastoparan, is G protein activator via Gαi and Gαo stimulation.

(CAS: 1802088-50-1)

NCT-501 is a potent and selective inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1) with IC50 of 40 nM.

(CAS: 1628260-79-6)

GLPG-1690, an imidazopyridine derivative, has been found to be a ENPP2 protein inhibitor that could probably be effective as an anti-inflammatory agent and is u...

CAS 264233-05-8 CID 2745687

CID 2745687
(CAS: 264233-05-8)

CID 2745687 has been found to be a GPR35 antagonist and could probably be used in immune or gastrointestinal system regulation.

Chemical Structure

CAS 21373-30-8 6-Hydroxy-DL-DOPA

Quick Inquiry

Verification code

Featured Items